2d:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/0fma7nlq6immz.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/1chr5wkk3j58k.js","/_next/static/immutable/chunks/37kmmh_zm4dov.js","/_next/static/immutable/chunks/311zvdjfxff-f.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js"],"default"] 2e:T5157,

Summary Table

Category	Details
Risk Factors	Primary maternal CMV infection during pregnancy (especially first trimester), seronegative mothers, daycare workers, mothers with young children, low socioeconomic status
Etiology	Vertical transmission of Cytomegalovirus (HHV-5), a double-stranded DNA virus of the Herpesviridae family; transmitted transplacentally, during delivery, or via breast milk
Patient Presentation	Most neonates (85-90%) are asymptomatic at birth; symptomatic infants present with jaundice, petechiae, hepatosplenomegaly, and microcephaly
Classic Physical Exam	Petechial rash ("blueberry muffin" appearance), hepatosplenomegaly, microcephaly, jaundice, chorioretinitis
Key Diagnostic Results	Urine or saliva CMV PCR positive within the first 21 days of life; head CT or ultrasound showing periventricular calcifications; thrombocytopenia on CBC
Management	Oral valganciclovir for 6 months in symptomatic neonates with CNS involvement; serial audiologic monitoring for all confirmed cases
Keywords	"Blueberry muffin rash," "periventricular calcifications," "sensorineural hearing loss," "failed newborn hearing screen," "PCR within 21 days of life"

1. Pathophysiology

CMV is a ubiquitous herpesvirus that establishes lifelong latency after primary infection. When a seronegative pregnant woman acquires CMV for the first time (primary infection), the transmission rate to the fetus is approximately 30-40%, and the risk of severe fetal disease is highest during the first trimester. Reactivation or reinfection with a different CMV strain can also cause congenital infection, but the disease severity is generally milder because pre-existing maternal antibodies offer partial protection.

Once the virus crosses the placenta, it has a strong tropism for rapidly dividing progenitor cells, particularly in the developing brain, inner ear, liver, and hematopoietic system. In the CNS, CMV targets the germinal matrix zone lining the ventricles, which is the proliferative zone for neuronal and glial precursors. This is exactly why the calcifications are periventricular in distribution, a hallmark finding that distinguishes congenital CMV from congenital toxoplasmosis (which produces diffuse, scattered intracranial calcifications). Destruction of these progenitor cells leads to migration abnormalities, lissencephaly, polymicrogyria, and ultimately microcephaly from impaired brain growth.

In the inner ear, CMV infects the stria vascularis and spiral ganglion neurons of the cochlea, producing sensorineural hearing loss (SNHL). This is the single most common sequela of congenital CMV and the leading nongenetic cause of SNHL in children. Critically, hearing loss may be progressive or late-onset, meaning a neonate can pass the initial hearing screen and still develop hearing impairment months to years later.

Hepatic involvement reflects viral replication in hepatocytes and biliary epithelium, causing a conjugated (direct) hyperbilirubinemia and elevated transaminases. The petechial rash and "blueberry muffin" spots result from dermal extramedullary hematopoiesis, a compensatory response to bone marrow suppression. Thrombocytopenia is common and results from both direct marrow infection and peripheral destruction.

Chorioretinitis occurs because CMV infects retinal pigment epithelium and neurosensory retina, producing white, necrotizing lesions that may threaten vision if the macula is involved.

2. Classification and Clinical Manifestation

Category	Presentation	Key Features	Long-Term Outcomes
Symptomatic at birth (10-15%)	Petechiae, jaundice, hepatosplenomegaly, microcephaly, chorioretinitis, IUGR	Periventricular calcifications on imaging, thrombocytopenia, elevated direct bilirubin, elevated ALT	SNHL (50-60%), intellectual disability (50-70%), seizures, cerebral palsy, vision impairment; mortality up to 5-10% in severely affected neonates
Asymptomatic at birth (85-90%)	Normal physical exam, no clinical signs	Diagnosis only if screening is performed (urine/saliva CMV PCR)	10-15% will develop late-onset SNHL or neurodevelopmental delay over the first several years of life
Asymptomatic with isolated SNHL	Passes initial physical exam but fails newborn hearing screen or develops hearing loss later	May be the only detectable sign; often bilateral but can be unilateral and asymmetric	Progressive hearing deterioration in a subset; early identification changes management

A critical testing point: the distinction between symptomatic and asymptomatic is not merely academic. Only symptomatic neonates with CNS involvement currently meet the treatment threshold for antiviral therapy. However, all confirmed congenital CMV cases, regardless of symptom status, require long-term audiologic follow-up because hearing loss can emerge or worsen over time.

3. Diagnostic Workup

Test	Role	Key Finding	Timing
Urine or saliva CMV PCR	Best initial and confirmatory test	Positive CMV DNA	Must be obtained within the first 21 days of life
Urine CMV culture (shell vial)	Traditional gold standard (historical)	Positive culture	Within first 21 days; slower turnaround than PCR
Head ultrasound / CT	Assess for CNS involvement	Periventricular calcifications, ventriculomegaly, lissencephaly, cerebellar hypoplasia	At diagnosis
MRI brain	Most sensitive for CNS abnormalities	Migration anomalies (polymicrogyria, lissencephaly), white matter disease	If head ultrasound is abnormal or for detailed prognostication
CBC with differential	Assess hematologic involvement	Thrombocytopenia, anemia, sometimes leukopenia or atypical lymphocytes	At diagnosis
Hepatic panel	Assess liver involvement	Elevated ALT, conjugated hyperbilirubinemia	At diagnosis
Ophthalmologic exam	Screen for chorioretinitis	White necrotizing retinal lesions	At diagnosis, then periodically
Auditory brainstem response (ABR)	Baseline hearing assessment	Sensorineural hearing loss (unilateral or bilateral)	At diagnosis, then every 6 months until age 3, then annually until age 6

The diagnostic cornerstone is CMV PCR from urine or saliva collected before 21 days of life. This cutoff is essential because CMV can be acquired postnatally (through breast milk or contact), and a positive PCR after 21 days cannot reliably distinguish congenital from postnatal infection. If a child older than 21 days is suspected of having congenital CMV, the next step is to check the dried blood spot (Guthrie card) from the newborn metabolic screen using retrospective PCR testing, though sensitivity is lower.

Saliva PCR is highly sensitive but can yield false positives in breastfed infants due to CMV shed in breast milk. Therefore, a positive saliva PCR should be confirmed with a urine specimen before establishing the diagnosis.

Once congenital CMV is confirmed, neuroimaging is performed to determine whether CNS disease is present, as this drives the treatment decision. Head ultrasound is a reasonable first-line imaging modality, but MRI is superior for detecting cortical migration abnormalities and white matter lesions that ultrasound may miss.

Maternal serology (CMV IgM and IgG with avidity testing) can help determine whether the mother had a primary infection during pregnancy. Low IgG avidity indicates recent primary infection (within the past 3-4 months), while high avidity suggests remote infection or reactivation. However, maternal serology is a supporting tool; it does not confirm or exclude congenital infection in the neonate.

4. Management and Treatment

Clinical Scenario	Treatment	Dose	Duration	Monitoring
Symptomatic with CNS involvement	Oral valganciclovir	16 mg/kg/dose, twice daily	6 months	CBC weekly for first 6 weeks, then monthly; hepatic panel; renal function
Symptomatic without CNS involvement	Consider valganciclovir	Same dosing	6 months (per recent guidelines)	Same monitoring protocol
Asymptomatic congenital CMV	No antiviral therapy	N/A	N/A	Serial hearing assessments and developmental follow-up
All confirmed cases	Audiologic monitoring	N/A	ABR every 6 months until age 3, then annually until age 6	Detect progressive or late-onset SNHL

Valganciclovir is the oral prodrug of ganciclovir and is the preferred antiviral because it can be given enterally. Intravenous ganciclovir (6 mg/kg/dose IV every 12 hours) is reserved for neonates who cannot tolerate oral medication. The landmark trial demonstrating benefit showed that 6 months of valganciclovir improved hearing outcomes at 12 and 24 months and modestly improved neurodevelopmental scores compared to 6 weeks of treatment.

The primary dose-limiting toxicity is neutropenia, which occurs in up to 20% of treated infants. Neutrophil counts must be monitored weekly for the first 6 weeks. If the absolute neutrophil count drops below 500/mm$^3$, the drug should be held and restarted at the same dose once counts recover. Thrombocytopenia and hepatotoxicity are less common but also warrant surveillance.

Treatment should be initiated within the first month of life for optimal outcomes. Starting therapy beyond 1 month of age is associated with diminishing benefit, and antiviral treatment is generally not recommended if initiated after the neonatal period for congenital infection.

For long-term management, all children with confirmed congenital CMV need serial audiologic and developmental assessments regardless of initial symptom status. Hearing aids or cochlear implantation may be necessary for children with progressive bilateral SNHL. Ophthalmologic follow-up is indicated for those with chorioretinitis.

There is currently no licensed CMV vaccine, though several candidates are in clinical trials. Behavioral prevention for seronegative pregnant women includes hand hygiene after contact with young children's saliva and urine, which are the primary routes of horizontal CMV acquisition.

5. Differential Diagnosis and Distractors

Differential Diagnosis	Why It Is Similar	Key Discriminator
Congenital Toxoplasmosis	Also presents with intracranial calcifications, chorioretinitis, hepatosplenomegaly, and microcephaly or hydrocephalus	Toxoplasmosis produces diffuse/scattered calcifications (basal ganglia and cortex), while CMV causes periventricular calcifications. Toxoplasmosis has a higher rate of hydrocephalus. Maternal history of undercooked meat or cat exposure supports toxoplasmosis.
Congenital Rubella Syndrome	Sensorineural hearing loss, blueberry muffin rash, hepatosplenomegaly, microcephaly, eye findings	Rubella classically causes cataracts and cardiac defects (PDA, peripheral pulmonary stenosis), not chorioretinitis. Intracranial calcifications are rare in rubella. Rubella is now exceedingly uncommon in vaccinated populations.
Congenital Syphilis	Hepatosplenomegaly, rash, anemia, jaundice in a neonate	Syphilis rash is typically on palms and soles, associated with rhinitis ("snuffles"), osteochondritis, and periostitis. Periventricular calcifications are absent. Maternal RPR/VDRL is positive.
Neonatal Herpes Simplex (HSV)	Can present with hepatitis, thrombocytopenia, and CNS disease in the neonatal period	HSV presents later (typically after day 3-5 of life), often with vesicular skin lesions, seizures, and temporal lobe involvement on MRI rather than periventricular calcifications. CSF PCR for HSV is positive.
Congenital Zika Virus	Severe microcephaly with intracranial calcifications	Zika produces calcifications at the cortical-subcortical junction (not periventricular), with arthrogryposis and severe cortical thinning. Maternal travel to endemic area is the key exposure history.
Neonatal Alloimmune Thrombocytopenia (NAIT)	Isolated severe thrombocytopenia with petechiae in a neonate	NAIT presents with isolated thrombocytopenia without hepatosplenomegaly, calcifications, or other TORCH features. The infant is otherwise well-appearing.

6. Traps and High-Yield Pearls

The single most tested concept in congenital CMV is the 21-day diagnostic window. A vignette will describe a 2-month-old with sensorineural hearing loss and periventricular calcifications, then ask for the next step. Students who pick "urine CMV PCR" at that age are falling into the trap, because a positive result after 21 days cannot confirm congenital (versus postnatal) infection. The correct answer in that scenario is to retrieve the newborn dried blood spot (Guthrie card) for retrospective CMV PCR.

Another common pitfall involves confusing periventricular calcifications (CMV) with diffuse or basal ganglia calcifications (toxoplasmosis). When a vignette describes intracranial calcifications in a neonate, the location of the calcifications is the discriminator, not their mere presence.

Students also frequently miss that congenital CMV is the most common congenital infection overall and the leading nongenetic cause of sensorineural hearing loss in children. A vignette describing a child who fails a newborn hearing screen with no other risk factors should prompt consideration of congenital CMV, even without the classic "blueberry muffin" rash or hepatosplenomegaly.

The treatment trap involves prescribing antivirals to asymptomatic infants. Valganciclovir carries real toxicity (neutropenia), and current guidelines reserve treatment for symptomatic infants with CNS involvement. The exam tests whether you recognize that the benefit-risk calculus differs between symptomatic CNS disease and asymptomatic infection.

Finally, remember that hearing loss in congenital CMV can be delayed and progressive. A normal ABR at birth does not rule out future hearing impairment. This is why long-term audiologic surveillance is recommended for all confirmed cases, and it is the reason congenital CMV screening programs are gaining traction even for asymptomatic neonates.

1e:["$","$L2d",null,{"article":{"id":"7248d5e1-a0f9-4360-88a2-867eec72b8a2","title":"Cytomegalovirus pada Kehamilan","content":"$2e","category":"Reproduksi","created_at":"2026-05-16T10:40:31.167646+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]